PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human g...
April 07 2021 - 4:01PM
PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA,
Darmstadt, Germany, known in the United States as EMD Serono,
selected PRA’s remote patient monitoring platform to work in
combination with its human growth hormone (HGH) treatment system.
Under this agreement, PRA’s remote patient monitoring platform
backs Merck KGaA, Darmstadt, Germany’s HGH treatment system,
including growlinkTM, a mobile app for patients prescribed with HGH
treatment, and easypod® Connect, a secure platform for healthcare
professionals (HCP) in the field of endocrinology to monitor
patients’ adherence, review injection history, and share
information about patients’ progression with growth hormone
disorder.
“Patients and payers expect us to offer new
technologies, such as treatment-supporting apps, with the highest
levels of privacy and data security,” said Andre Musto, Senior Vice
President and Head of Cardiovascular Metabolism &
Endocrinology, Merck KGaA, Darmstadt, Germany. “With growlink and
easypod Connect, supported by PRA’s remote patient monitoring
platform, we can offer patients innovative tools to help manage
their condition and assure payers of the effective use of
treatments while fully respecting their privacy and data
security.”
Human growth hormone treatments are frequently
prescribed for children and adolescents with growth hormone
deficiency, a condition that impacts approximately 1:4,000 to
1:10,000 children1 each year in the U.S. Despite the prevalence of
growth hormone deficiency and treatment options, one of the biggest
challenges is ensuring patients’ adherence to the regimen. Adding
this layer of technology to HGH treatments better facilitates
patient engagement, helps HCPs make better use of patient visits,
and ensures the treatment is taken regularly and at the right
dosage, optimizing treatment outcome and driving payer
confidence.
In a real-world setting, an HCP would use easypod
Connect to invite patients to download the mobile app, growlink.
Then the patient downloads the mobile app, signs an eConsent form
on the app, and syncs the app with Merck KGaA, Darmstadt, Germany’s
HGH injector medical device, easypod. This device is able to
self-regulate the appropriate dosage of HGH based on the treatment
protocol. The four-part system – Merck KGaA, Darmstadt, Germany’s
mobile app (growlink), connected device (easypod), and HCP platform
(easypod Connect ) underpinned by PRA’s remote patient monitoring
technology – enables HCPs to see an accurate picture of patients’
adherence, height, weight, and other outcomes while offering
patients a more convenient way to follow to their treatment regimen
and manage their condition.
“For many years, PRA has been focused on designing
an end-to-end digital health platform that supports mobile
healthcare delivery, such as remote patient monitoring,” said Kent
Thoelke, Executive Vice President and Chief Scientific Officer, PRA
Health Sciences. “Our collaboration with Merck KGaA, Darmstadt,
Germany to support growlink and easypod Connect is an example of
how the industry is advancing with the patient at the center of our
innovation.”
PRA hosted a webinar called, How Digital
Therapeutics and Remote Patient Monitoring Can Drive Pharmaceutical
Product Differentiation, to help create differentiation. Access the
replay webinar today.
For more information about PRA’s remote patient
monitoring solutions, visit www.prahs.com.
1 Stanley T. Diagnosis of Growth Hormone Deficiency
in Childhood. HHS Public Access. Available at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279941/
About PRA Health Sciences
PRA Health Sciences is one of the world’s leading
global contract research organizations by revenue, providing
outsourced clinical development and data solution services to the
biotechnology and pharmaceutical industries. PRA’s global clinical
development platform includes more than 75 offices across North
America, Europe, Asia, Latin America, Africa, Australia and the
Middle East and more than 19,000 employees worldwide. Since 2000,
PRA has participated in approximately 4,000 clinical trials
worldwide. In addition, PRA has participated in the pivotal or
supportive trials that led to U.S. Food and Drug Administration or
international regulatory approval of more than 95 drugs. To learn
more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Laurie Hurst, Sr. Director,
Communications and Public Relationshurstlaurie@prahs.com | +1 (919)
786-8435
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2023 to Oct 2024